Pavitra Keshavan

Pavitra Keshavan

Auto-generated profile, based on publicly available information

Pavitra Keshavan

GSK, Siena, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AHAlejandro Hoberman
Alejandro Hoberman
JAJibran Atwi
Jibran Atwi
PSPeter Silas
Peter Silas
RPRosa Prato
Rosa Prato
SBSamantha Bosis
Samantha Bosis
PKPavitra Keshavan
Pavitra Keshavan
Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16–18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16–18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.

6 November 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
DSDebasish Saha
Debasish Saha
LCLaura Tomasi Cont
Laura Tomasi Cont
NKNicola P Klein
Nicola P Klein
JMJudith M Martin
Judith M Martin
ECElisa Cinconze
Elisa Cinconze
KKKeshaw Kumar
Keshaw Kumar
Background: Meningococcal serogroup B (MenB) vaccine, 4CMenB, has been licensed in the United States (US) since 2015 for individuals aged 10–25 years. This study assessed 4CMenB in US infants when administered concomitantly with pneumococcal vaccine PCV13 and other routine infant vaccines (RIVs). Methods: This phase 3b, observer-blind, placebo-controlled study (NCT03621670) randomized (2:1) healthy US infants to receive either 4CMenB administered concomitantly with PCV13 and other RIVs (N=786; 4CMenB+RIVs group) or placebo with PCV13 and other RIVs (N=409; Placebo+RIVs group) at 2, 4, 6, and 12 months of age. Primary objectives were to demonstrate the sufficiency of immune responses to MenB indicator strains (individually and combined), to demonstrate the non-inferiority of immune responses to PCV13 administered with 4CMenB+RIVs versus PCV13 plus placebo+RIVs, and assess safety. Immune responses to RIVs administered with 4CMenB+PCV13 versus RIVs plus placebo+PCV13 were investigated as secondary objectives. Results: Pre-specified sufficiency criteria post-dose 3 and post-dose 4 were met for each MenB strain except NHBA and the composite response. Percentages of seroprotected participants (human serum bactericidal assay titers ≥lower limit of quantitation) against MenB indicator strains post-dose 4 were 86.1–99.6% in 4CMenB+RIVs group versus 0.0–2.8% in Placebo+RIVs group. The success criterion for achieving immunological non-inferiority of PCV13 was met, and concomitant 4CMenB administration did not adversely affect immune responses to other RIVs. 4CMenB co-administered with PCV13 and RIVs was generally well tolerated, with no safety concerns identified. Conclusions: 4CMenB was well tolerated and immunogenic in US infants, producing no immunological interference when co-administered with other recommended vaccines.

30 January 2026 in Pharmaceutical Statistics
Verified
Journal Article
Open access
MAMeike Adani
Meike Adani
SNSilvia Noirjean
Silvia Noirjean
ACAndrea Callegaro
Andrea Callegaro
PKPavitra Keshavan
Pavitra Keshavan
MCMarco Costantini
Marco Costantini
During a vaccine development program, if the assay used to measure immunological endpoints is changed, ideally, a bridging study is performed to establish the relationship between results obtained with the new and previous assay. However, this is not always feasible, and when bridging study data are absent, this can limit the ability to use historical study information to strengthen evidence generated in the clinical program. We present a case study on GSK's quadrivalent meningococcal vaccine (MenACWY‐CRM), where the immunogenicity assay was changed over time. A large amount of study data was collected in randomized controlled clinical trials, providing a valuable source of information to support vaccine development, but the introduction of the new assay complicated the comparison of antibody responses across studies. Several causal inference techniques, developed for the analysis of non‐randomized studies, can be used to estimate the assay bridging effect and, as observed in our case study, address the presence of confounding factors resulting from pooling group data from different sources. Cutting‐edge propensity score‐based methods were evaluated, highlighting their advantages and limitations. Within the family of propensity score weighting methods, the widely used inverse probability weighting was compared to the novel overlap weighting technique. The latter was shown to resolve the problem of extreme weights in a situation where there was poor overlap in covariate distribution between two groups. Automated selection of specific methods should be approached with caution, carefully considering the different estimands targeted by different methods.